Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Nasopharyngeal Carcinoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Ovarian Neoplasms 13 Fallopian Tube Neoplasms 8 Triple Negative Breast Neoplasms 7 Pancreatic Neoplasms 7 Neoplasms 7 Neoplasm Metastasis 6 Prostatic Neoplasms 5 Endometrial Neoplasms 4 Neuroendocrine Tumors 3 Carcinoma, Ovarian Epithelial 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Glioma 2 Glioblastoma 2 Cholangiocarcinoma 2 Advanced Solid Tumor 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 SCLC,Extensive Stage 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1

Interventions

Cisplatin 25 Gemcitabine 22 Radiotherapy, Intensity-Modulated 20 toripalimab 18 Drug Therapy 9 Radiotherapy 8 Capecitabine 8 nimotuzumab 7 camrelizumab 7 Magnetic Resonance Spectroscopy 7 spartalizumab 6 Specimen Handling 6 Endoscopy 5 Docetaxel 5 Immune Checkpoint Inhibitors 4 Biopsy 4 pembrolizumab 3 Surgical Procedures, Operative 3 Platinum 3 Nivolumab 3 Fluorouracil 3 Blood Specimen Collection 3 1,2-diaminocyclohexaneplatinum II citrate 3 tislelizumab 2 sintilimab 2 irinotecan sucrosofate 2 apatinib 2 S 1 (combination) 2 Radiation 2 Phantoms, Imaging 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04825990 2022-04-07

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡